Skip to main content
. Author manuscript; available in PMC: 2018 Mar 7.
Published in final edited form as: Cancer Res. 2013 Dec 4;74(3):884–895. doi: 10.1158/0008-5472.CAN-12-3583

Figure 1. MET and RON protein expression and effect of LY2801653 on NSCLC cell lines.

Figure 1

A. Immunoblots for protein expression from lysates of the NSCLC cell lines using antibodies against MET, RON. MET expression is detected at 145 kDa. RON expression is detected at 150 kDa. B. Effect of LY2801653 on growth inhibition of NSCLC cells in vitro. Percentage of viable cells was determined relative to the untreated control, which had same dose of DMSO. Each data point represents the mean value and SEM of 6 replicate wells. A549, H1703 and H1993 are sensitive cell lines against LY2801653. C. Effect of crizotinib on growth inhibition of NSCLC cells in vitro. A549, H1703 and H1993 are sensitive cell lines against LY2801653, but IC50 of crizotinib was higher than IC50 of LY2801653 in each cell line.

HHS Vulnerability Disclosure